Kaplan–Meier and log-rank tests showed that osteosarcoma patients with miR-150-low or IGF2BP1-high expression had shorter overall and disease-free survivals than those with miR-150-high or IGF2BP1-low expression (all P < 0.001, Fig. 2a, b, c and d). This evidence concerns the gene IGF2BP1 and osteosarcoma.